Skip to main content

Type I Hypersensitivity

5
Pipeline Programs
1
Companies
11
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
4
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
7 programs
1
4
Grass MATAMPLPhase 21 trial
RagweedMATAMPLPhase 21 trial
Tree MATA MPLPhase 21 trial
TreeMATA MPLPhase 21 trial
Tree MATA MPLPhase 11 trial
+2 more programs
Active Trials
NCT07412990Recruiting1,000Est. Oct 2028
NCT00133146Completed41Est. Nov 2005
NCT00104377Completed70Est. Nov 2005
+8 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Allergy TherapeuticsRagweed MATA MPL
Allergy TherapeuticsRagweedMATAMPL
Allergy TherapeuticsGrass MATAMPL
Allergy TherapeuticsGrass MATA MPL
Allergy TherapeuticsTreeMATA MPL
Allergy TherapeuticsTree MATA MPL
Allergy TherapeuticsGrass MATA MPL
Allergy TherapeuticsRagweed MATA MPL
Allergy TherapeuticsTree MATA MPL
Allergy TherapeuticsGrass MATA MPL
Allergy TherapeuticsGrass MATA MPL

Clinical Trials (11)

Total enrollment: 2,389 patients across 11 trials

NCT00423787Allergy TherapeuticsRagweed MATA MPL

Efficacy and Safety/Tolerability of Ragweed MATA MPL

Start: Mar 2007Est. completion: Mar 2008993 patients
Phase 3Completed
NCT00258635Allergy TherapeuticsRagweedMATAMPL

Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test

Start: Nov 2005Est. completion: Aug 200669 patients
Phase 2Completed
NCT00133159Allergy TherapeuticsGrass MATAMPL

Different Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Grass Pollen

Start: Sep 2005Est. completion: Nov 200568 patients
Phase 2Completed
NCT00133146Allergy TherapeuticsGrass MATA MPL

Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine

Start: Sep 2005Est. completion: Nov 200541 patients
Phase 2Completed
NCT00113750Allergy TherapeuticsTreeMATA MPL

Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen

Start: Jul 2005Est. completion: Dec 200570 patients
Phase 2Completed
NCT00118625Allergy TherapeuticsTree MATA MPL

Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Tree Pollen Allergy Vaccine

Start: Jul 2005Est. completion: Sep 200540 patients
Phase 2Completed
NCT00104377Allergy TherapeuticsGrass MATA MPL

Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen

Start: Mar 2005Est. completion: Nov 200570 patients
Phase 2Completed
NCT00116285Allergy TherapeuticsRagweed MATA MPL

Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin Prick Testing

Start: Jun 2005Est. completion: Jun 200512 patients
Phase 1Completed
NCT00107705Allergy TherapeuticsTree MATA MPL

Assessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testing

Start: Apr 2005Est. completion: May 200512 patients
Phase 1Completed
NCT00104390Allergy TherapeuticsGrass MATA MPL

Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing

Start: Mar 2005Est. completion: Apr 200514 patients
Phase 1Completed
NCT07412990Allergy TherapeuticsGrass MATA MPL

GRASS (Grass MATA MPL Real-world Assessment Study)

Start: Mar 2026Est. completion: Oct 20281,000 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 2,389 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.